Inflammatory and prothrombotic states in obese children of European descent

Sophie Stoppa-Vaucher1, Mirjam A Dirlewanger, Christoph A Meier

  • 1Pediatric Endocrine and Diabetes Unit, Children's Hospital, University Hospitals and Faculty of Medicine, Geneva, Switzerland.

Insights

Obese children, even before puberty, show early signs of inflammation and blood clotting issues. These inflammatory and prothrombotic states are linked to increased cardiovascular risk factors in childhood.

Area of Science:

  • Pediatric Endocrinology
  • Cardiovascular Health
  • Inflammation Research

Background:

  • Adipose tissue dysfunction in obesity can trigger chronic inflammation and coagulation abnormalities.
  • These alterations are implicated in the development of insulin resistance, atherosclerosis, and thrombosis.
  • Early identification of these states in children is crucial for cardiovascular risk management.

Purpose of the Study:

  • To investigate the presence of inflammatory and prothrombotic states in obese children.
  • To assess the interrelationship between these states and their onset.
  • To identify specific biomarkers associated with these conditions in pediatric obesity.

Main Methods:

  • Cross-sectional study involving 61 obese children and lean controls (ages 6-16).
  • Measurement of pro/anti-inflammatory cytokines (IL-1Ra, MCP-1, IL-6, IL-10, IP-10) and hemostasis parameters (PT, aPTT, fibrinogen, D-dimer, ETP).
  • Assessment of insulin resistance using homeostatic model assessment (HOMA) and family cardiovascular risk factors.

Main Results:

  • Obese children exhibited significantly elevated levels of anti- (IL-1Ra) and pro-inflammatory cytokines (MCP-1, IL-6) compared to controls, even pre-puberty.
  • Hemostasis was altered in obese children, with increased fibrinogen, D-dimer, and endogenous thrombin potential (ETP), and a shortened prothrombin time (PT).
  • No significant correlation was found between cytokine levels and hemostasis parameters, except for IL-6 and fibrinogen.

Conclusions:

  • Obese children, as young as 6 years, exhibit both inflammatory and prothrombotic states.
  • These conditions are present in both prepubertal and pubertal obese children.
  • Further research is needed to determine if cytokines IL-1Ra, MCP-1, and ETP can predict future diabetes and atherosclerosis development.

Related Concept Videos

Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...